EMA Withdrawn: Atripla (efavirenz;emtricitabine;tenofovir disoproxil fumarate) — Gilead Sciences Ireland UC

View source ↗

Summary

EMA has withdrawn Atripla (efavirenz; emtricitabine; tenofovir disoproxil fumarate) from the market; therapeutic area: HIV infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate)

Snippet

Status: Withdrawn. Therapeutic area: HIV Infections. MAH: Gilead Sciences Ireland UC. Decision date: 17/08/2021